Snowden Capital Advisors’s Immunogen Inc IMGN Stock Holding History

Snowden Capital Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-109	Closed	–	–	2155
2021 Q4	$0	Buy	+109	New	+$677	﹤0.01%	2185

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Snowden Capital Advisors's IMGN Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Immunogen Inc (IMGN) in Q1 2022, closing a stake of 109 shares.

Snowden Capital Advisors first reported a position in IMGN in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 217 funds tracked by Wall St. Rank hold IMGN as of Q1 2022.

Snowden Capital Advisors reported no remaining Immunogen Inc position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 109 Immunogen Inc shares in Q1 2022.
Snowden Capital Advisors first reported a position in Immunogen Inc in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Immunogen Inc position peaked at $0 in Q4 2021.
217 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.